Manufacturing, Fill/Finish

Nov 14, 2008
BioPharm International
By BioPharm International Editors
The European Medicines Agency (EMEA) has granted license approval to Bayer HealthCare LLC (Bayer, Berkeley, CA) for its new sterile filling facility on its Berkeley, CA, campus.
Dec 01, 2007
BioPharm International
By BioPharm International Editors
The second of a two part article.
Aug 02, 2007
BioPharm International
By BioPharm International Editors
Adjuvant-caused vaccine reactions are one of the most important barriers to better acceptance of routine prophylactic vaccination.
Aug 01, 2007
BioPharm International
By BioPharm International Editors
Drug delivery technologies have the potential to enable drug candidates with poor pharmaceutical or biopharmaceutical properties, both for macromolecule and traditional compounds. While there have been many success stories to date, the future offers even more promise. In this article, the author surveys the top ten areas in drug delivery looking forward.
Nov 09, 2006
The many benefits of disposable technologies, such as significant savings in time, labor and capital, as well as ease of scalability and flexibility, have led to the growing trend of adopting disposable technologies in bioprocess manufacturing processes.
Oct 01, 2006
BioPharm International
By BioPharm International Editors
Formulations for pulmonary inhalation comprise spherical, porous particles that are 1–3 microns in diameter.
Jul 01, 2006
BioPharm International
By BioPharm International Editors
Disposables require less space than conventional equipment, and they can be assembled offsite into complete process trains.
Jun 27, 2006
BioPharm International
On August 12, 2003, Johnson & Johnson began recalling certain batches of its anemia drug, Eprex (epoetin alfa, sold as Procrit in the US), in most countries outside of the United States.
Jun 27, 2006
BioPharm International
By BioPharm International Editors
A symposium at the AAPS National Biotechnology Conference in Boston, June 19-22, 2006, addressed key concerns and new developments in manufacturing biologic products in a sterile environment.
native1_300x100
lorem ipsum